Results 81 to 90 of about 3,787,231 (262)
Assessing the quality of research [PDF]
Jill, Morrison, John, Bligh
openaire +2 more sources
Presentation from Bernard Rentier in the Research Assessment panel at the Open Science FAIR 2019 (Porto, 16-17 September 2019).
openaire +2 more sources
Immunoglobulin Depletion and Recovery Following Blinatumomab in Infants With KMT2A‐Rearranged ALL
ABSTRACT Adding blinatumomab to standard chemotherapy for infants with KMT2A‐rearranged acute B‐cell lymphoblastic leukemia (KMT2A‐r B‐ALL) improves outcomes. Although blinatumomab impairs immunoglobulin G (lgG) production, increasing infection susceptibility, IgG recovery remains poorly understood.
Miguel Vieira Martins +14 more
wiley +1 more source
The San Francisco Declaration on Research Assessment (DORA) in Nursing Science. [PDF]
O'Connor S.
europepmc +1 more source
ABSTRACT Neuroblastoma's complex, heterogeneous biology poses significant diagnostic and therapeutic challenges, often requiring caregivers to absorb complex information and participate in time‐sensitive decisions. However, caregivers often feel unprepared to evaluate options.
Vickie Buenger +8 more
wiley +1 more source
Endometrium as Control of Endometriosis in Experimental Research: Assessment of Sample Suitability. [PDF]
Szegeczki V +8 more
europepmc +1 more source
ABSTRACT Background Neurotoxicity is a rare, often dose‐limiting adverse effect of methotrexate (MTX) therapy that disproportionally affects Latino children. Factors contributing to the observed disparity are not well understood. This study leveraged admixture mapping to identify genetic regions associated with MTX‐related neurotoxicity susceptibility ...
Rachel D. Harris +24 more
wiley +1 more source
Collective health research assessment: developing a tool to measure the impact of multistakeholder research initiatives. [PDF]
Kork AA +10 more
europepmc +1 more source
Impact of Metastatic Patterns on Survival and Response to Therapy in Neuroblastoma
ABSTRACT Background While the presence of metastases in neuroblastoma (NB) is a well‐established prognostic factor, the clinical significance of dissemination patterns and tumour burden and their impact on response and survival remains poorly understood.
Mariona Morell‐Daniel +15 more
wiley +1 more source

